Delivering on the Promise of Targeted Protein Degradation
Cowen 42nd Annual Health Care Conference March 9, 2022
Forward-looking Statements and Intellectual Property
Forward-looking Statements
The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.
Intellectual Property
C4 Therapeutics, Inc. owns various registered and unregistered trademarks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation are referred to without the symbols ® and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
© 2022 C4 Therapeutics, Inc. | | 2 |
Targeted Protein Degradation Has the Potential to Transform Treatment of Disease
TPD Has an Expansive | |
Target Landscape | |
~85% | 85% of proteins are |
currently undruggable or |
poorly drugged
TPD Offers a Powerful
Modality
Benefits of genetic knockdown with a small molecule approach
C4T's TORPEDO platform creates therapeutic candidates that have the potential to improve patient care
Overcome Resistance
Drug Undruggable Targets
Improve Treatment Options
Source: Hopkins, A., Groom, C. The druggable genome. Nat Rev Drug Discov 1, 727-730 (2002).
© 2022 C4 Therapeutics, Inc. | | 3 |
Our TORPEDO Platform Efficiently Designs Potent Targeted Protein Degrader Medicines
Elements | Benefits |
Focus on Catalytic
Efficiency
Ability to Design, Analyze & Predict Degrader Performance
Investment in Cereblon as E3 Ligase
Ability to Develop Both MonoDAC & BiDAC Degraders
Optimization of overall degradation process results in maximal efficacy
Rapid delivery of potent drug candidates through informed and efficient drug discovery
Cereblon is expressed in all tissues and cellular compartments, thereby providing the largest target selection opportunity
Flexibility to address different targets with tailored approach
© 2022 C4 Therapeutics, Inc. | | 4 |
C4T is Well Positioned to Deliver on the Promise of Targeted Protein Degradation to Transform Patient Care
Leading in
TPD Science
World-class
medicinal
chemistry coupled with fundamental enzymology approach
Validated
Platform
TORPEDO platform
enables efficient
optimization of MonoDAC and BiDAC degraders
Oncology-Focused Clinical Pipeline
Transform patient care by targeting undrugged or poorly drugged targets
Strong Foundation to Support Growth
Capabilities across
discovery and
clinical coupled with
experience in
strategic
partnerships and strong balance sheet
*Cash, cash equivalents, and marketable securities were $451.5M as of 12/31/21
© 2022 C4 Therapeutics, Inc. | | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
C4 Therapeutics Inc. published this content on 09 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 March 2022 15:01:10 UTC.